

FDA's Pharmaceutical Inspectorate

**Association of Food and Drug Officials
June 2006**

**Susan M. Setterberg
Regional Director, Central Region
Food and Drug Administration**



Pharmaceutical Inspectorate

- Where we started
 - Part of the Quality Drug Initiative
 - Summer 2002 initiated discussions
 - Dedicated investigators
 - Initiated training for Process Analytical Technology
-



Pharmaceutical Inspectorate

□ Desired Goal

- Establish a staff of highly trained individuals that focus a majority of their time on conducting human and animal drug quality inspections on high risk firms.
-



Pharmaceutical Inspectorate

- Desired Goal
 - Establish a close working relationship between all individuals in the field and centers
-




Pharmaceutical Inspectorate

□ Process

- Review of position descriptions for current field specialists
 - Examination of data for a year of accomplishments
 - Current workforce review
 - Reviewed the field training programs
-

Pharmaceutical Specialists by District in 2003 (CSO Drug and Commissioned Corp 05)





Pharmaceutical Inspectorate

□ Findings

- Current position descriptions appropriate
 - Most specialists predominantly focused in their specific programs
 - Number of Potential candidates good
 - Certification Program could be expanded
-



Pharmaceutical Inspectorate

- Training Development Steps
 - Used Existing Level I
 - Initiated Level II Certification for the drug program
 - Expanded the Field Certification Program to a new level
-



Pharmaceutical Inspectorate

- Certification Program Components
 - Curriculum Defined
 - Formal National Courses, Web based training, OJT, District Courses
 - Assessments
 - Certification Board
 - Course Advisory Group
 - Continuing Education
-



Pharmaceutical Inspectorate

- Curriculum – General Considerations
 - Set minimum expectations
 - Extensive review
 - Courses meet Continuing Education Standards
 - Lecturers to include experts in government, academia and industry
-



Pharmaceutical Inspectorate

- Competencies for the PI (modules)
 - Regulating Pharmaceutical Quality and Relationship to FDA's Mission
 - Risk Management
 - Advanced Quality Systems
 - Pharmaceutical Science
 - Current Regulatory Programs and Procedures
 - Technology
 - Investigational
-



Pharmaceutical Inspectorate

- Regulating Pharmaceutical Quality and Relationship to FDA's Mission
 - Philosophy
 - Risk Management
 - Current concepts related to product quality
 - How to apply knowledge to inspections
 - GMP compliance
 - State of control
 - Impact of GMP violations
-



Pharmaceutical Inspectorate

- Advanced Quality Systems
 - Quality management techniques
 - Implementation of quality systems approaches to pharmaceutical production
 - Pharmaceutical Science
 - Science underlying approaches to controlling product quality
 - Causes of variability
-



Pharmaceutical Inspectorate

- Current Regulatory Programs and Procedures
 - Integration of review and inspectional programs regarding product quality
 - Critical thinking
 - Inspectional discretion
 - Effective communication of complex issues
-



Pharmaceutical Inspectorate

□ Technology

- Science and technology advances in pharmaceutical manufacturing
 - How advances enhance quality of inspections
 - Impact on inspectional approach
 - Best practices
 - Future technological developments and impact on production
-



Pharmaceutical Inspectorate

□ Investigational

- Identifying new knowledge needed
 - Sources of information
 - Investigational technique differences across program areas
-



Pharmaceutical Inspectorate

□ Objectives of Training

The PI participants

- are capable of making judgments about a firm's risk management programs, product and process knowledge, process capability, and robustness of quality systems.
-



Pharmaceutical Inspectorate

□ Objectives of Training

The PI participants

- will use risk assessment in conducting inspections and making recommendations.
 - will establish a network with Center Product Specialists and Technical Experts.
-



Pharmaceutical Inspectorate

□ Results of Program

- Well trained workforce
 - Mechanism to train on new technologies
 - Closer interactions between Centers and ORA
 - Consistency
 - Roll out policy changes
-




Pharmaceutical Inspectorate

- Status of Program
 - Level II Certifications
 - Auditors
 - Curriculum completion and Details
 - Level III (PI) Candidates
-

Pharmaceutical Inspectorate Candidates and Graduates

April 2006





Pharmaceutical Inspectorate

□ What's next

- Updates for the PI
 - Second Class launch
 - Reach back to Level I and II training with concepts
 - Video Conferences for the Field and Centers
 - Compliance Officer course
-



Pharmaceutical Inspectorate

□ What's Next

■ Quality Management System

- PI Quality Task Force identified as an adjunct to the Council on Pharmaceutical Quality
 - Assure currency of existing procedures
 - Adopt new procedures for CSO/Center interactions
 - Communications
 - Continuous Education
 - Evaluation and Improvement
-



Pharmaceutical Inspectorate

http://www.fda.gov/cder/gmp/gmp2004_finalreport2004.htm

<http://www.fda.gov/cder/gmp/gmp2004/pharma.inspect.htm>

<http://www.fda.gov/cder/gmp/21stcenturysummary.htm>

<http://www.fda.gov/cder/gmp/pharminspectorate.htm>

<http://www.fda.gov/cder/gmp/PI-q&a.htm>

<http://www.fda.gov/cder/gmp/index.htm>



Pharmaceutical Inspectorate

Thank you!
